Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule
Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V
Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z
Guardion Provides Update on Strategy, Business Plans and Initiatives
Guardion Announces Virtual Annual Meeting of Stockholders
Guardion Health Sciences Reports Results of Operations for Quarter Ended June 30, 2020
Guardion Health Sciences to Report Second Quarter 2020 Financial Results on August 12, 2020
Guardion Health Sciences Completes Delivery of $875,000 Order to Malaysian Corporate Customer
Guardion Health Sciences Reports First Quarter 2020 Financial Results and Provides Corporate Update
Guardion Health Sciences to Present at the April 2020 Virtual Investor Summit
Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant Complex
Guardion Health Sciences Reports 2019 Year End Results and Provides Corporate Update and Overview
Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants
Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering
Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering
Guardion® Announces Statistically Significant Blood Assay Study Results
Guardion Health Sciences Acquires the NutriGuard Brand of Products
Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test
Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering
Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering
Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union
Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’
Guardion’s Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma
Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China
Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering
Results of Lumega-Z Data to be Presented at ARVO
Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering
Guardion Health Sciences Receives Methods Patents to Standardize Vision Testing
Guardion Health Sciences Exhibiting at Caribbean Eye Meeting
Guardion Health Sciences Closes $5 Million Common Equity Financing
Guardion Health Sciences acquires VectorVision
Guardion Health Sciences announces completion of Series B funding round, raising over $3 million
International Carotenoid Society honors Advisory Board Members with Fellowship Awards
Guardion Health Sciences signs Letter of Intent to acquire VectorVision
Guardion Health Sciences, Inc. completes registration with SEC, becomes a Public Reporting Company
Guardion Health Sciences receives patent for its diagnostic device, the MapcatSF
P Dee G Stephenson, M.D. joins Guardion Health Sciences Medical Advisory Board
Bridgitte Shen Lee, O.D. joins Guardion Health Sciences Medical Advisory Board
Guardion Health Sciences Files Form S-1 Registration Statement under the Securities Act of 1933
Macular pigment specialists, Guardion Health Sciences appoints Gordon Bethwaite as Vice President
Col (R) Donald A. Gagliano, MD, MHA, FACHE, CPC joins Guardion’s Science Advisory Board
Macular Carotenoids Conference 2013
GHS Scientists to Present at the Macular Carotenoids & AMD Conference 2011